Phase I trial of tandem chemotherapy cycles as consolidation therapy for high-risk epithelial ovarian and primary peritoneal cancer utilizing intraperitoneal paclitaxel/IV [intravenous] cyclophosphamide followed by IV topotecan/intraperitoneal cisplatin/IV melphalan using hematopoietic stem cell support
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cisplatin; Cyclophosphamide; Melphalan; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Oct 2014 Biomarkers information updated
- 13 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.